Apple (NASDAQ:AAPL), Adobe (NASDAQ:ADBE) upgrade rating ke BUY

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga Apple (NASDAQ:AAPL), Adobe (NASDAQ:ADBE) selama beberapa minggu terakhir, kami memutuskan untuk menaikkan ratingnya menjadi BUY dan memasukan ke dalam portfolio kami.

Apple (NASDAQ:AAPL) Price: 148$ upgrade to BUY

FA: pemasukan iklan naik 3x lipat setelah perubahan privacy policy
TA: Weekly trend naik. Elliot wave July 2022 TP (Target price) 203

Adobe (NASDAQ:ADBE) . Price:643$. upgrade to BUY

FA: business model and pertumbuhan yang kuat, pass checklist
TA: Elliot Wave pattern with target price 960

========================================================

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

After fundamental analysis and technical analysis of the price movements of Apple (NASDAQ:AAPL), Adobe (NASDAQ:ADBE) for the past few weeks, we have decided to increase the rating to BUY and include it in our portfolio.

Apple (NASDAQ:AAPL) Price: 148$ upgrade to BUY

FA: ad revenue tripled after privacy policy change
TA: Weekly trend is up. Elliot wave July 2022 TP (Target price) 203

Adobe (NASDAQ:ADBE) . Price:643$. upgrade to BUY

FA: business model and strong growth, pass checklist
TA: Elliot Wave pattern with target price 960

Shutterstock (NYSE:SSTK), Docebo (NASDAQ:DCBO) upgrade rating ke BUY

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga Shutterstock (NYSE:SSTK), Docebo (NASDAQ:DCBO) selama beberapa minggu terakhir, kami memutuskan untuk menaikkan ratingnya menjadi BUY dan memasukan ke dalam portfolio kami.

Shutterstock (NYSE:SSTK) Price: 121.81$ upgrade to BUY

Breakout SMA 20 di atas 120

Docebo (NASDAQ:DCBO). Price:78.47$. upgrade to BUY

Bullish island, tunggu resistance di 79.52$.

========================================================

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

After fundamental analysis and technical analysis (Technical Analysis) price movements of Shutterstock (NYSE:SSTK), Docebo (NASDAQ:DCBO) for the past few weeks, we decided to raise their rating to BUY and include them in our portfolio.

Shutterstock (NYSE:SSTK) Price: 121.81$ upgrade to BUY

20 SMA breakout above 120

Docebo (NASDAQ:DCBO). Price:78.47$. upgrade to BUY

Bullish island, wait for the resistance at 79.52$.

Crocs (NASDAQ:CROX) downgrade rating ke SELL, Baidu (NASDAQ:BIDU) upgrade rating ke BUY

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga Crocs (NASDAQ:CROX) selama beberapa minggu terakhir, kami memutuskan untuk menurunkan ratingnya menjadi SELL dan mengeluarkan dari portfolio kami. Sedangkan Baidu (NASDAQ:BIDU) kami menaikkan ratingnya menjadi BUY dan memasukan ke dalam portfolio kami.

Crocs (NASDAQ:CROX) downgrade to SELL

TA: double top. TP dibawah SMA200. MACD red historically long. TP 88-101
FA: financial leverage high, FCF/net income <1

Baidu ADR (NASDAQ:BIDU) Upgrade to BUY

TA: sudah diatas SMA50. breakout. uptrend
FA: all chklist pass, growth rate strong. monopoly search engine in China 75%

=====================================================

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

After fundamental analysis and technical analysis of the price movements of Crocs (NASDAQ:CROX) over the last few weeks, we have decided to downgrade it rating to SELL and remove it from our portfolio. Meanwhile for Baidu (NASDAQ:BIDU) we raised it rating to BUY and added it to our portfolio.

Crocs (NASDAQ:CROX) downgrade to SELL

TA: double top. TP below SMA200. MACD red historically long. TP 88-101
FA: high financial leverage, FCF/net income <1

Baidu ADR (NASDAQ:BIDU) Upgrade to BUY

TA: already above SMA50. breakouts. uptrend
FA: all checklist pass, strong growth rate. monopoly search engine in China 75%

Broadcom (NASDAQ:AVGO) dan Doximity (NYSE:DOCS) downgrade rating ke SELL, Kinder Morgan (NYSE:KMI), dan Exxon Mobile Corp (NYSE:XOM) upgrade rating ke BUY

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga Broadcom (NASDAQ:AVGO) dan Doximity (NYSE:DOCS) selama beberapa bulan terakhir, kami memutuskan untuk menurunkan rating mereka menjadi SELL dan mengeluarkan dari portfolio kami. Sedangkan Kinder Morgan (NYSE:KMI), dan Exxon Mobile Corp (NYSE:XOM) kami menaikkan rating mereka menjadi BUY dan memasukan ke dalam portfolio kami.

Broadcom (NASDAQ:AVGO) downgrade to SELL

TA: Relatively sideway. Target retract 462, daily, weekly 399
FA: Foundry overload dan masalah logistik dunia. Sell untuk rotasi sektor

Doximity (NYSE:DOCS) downgrade to SELL

TA: Touch SMA50, tetapi downtrend.
FA: Tidak ada perubahan dalam fundamental. To monitor on next earning Nov. Sell untuk rotasi sektor

Kinder Morgan (NYSE:KMI) Upgrade to BUY

TA: Momentum naik, RSI,MACD naik, Retrace di 17.3
FA: Qtrly positif. Cashflow ud positif. Permintaan minyak China tinggi, kemungkinan akan adanya ketegangan di laut cina selatan

Exxon Mobile (NYSE:XOM) Upgrade to BUY

TA: Bullish crossover. TP TA 65
FA: Rotasi sektor. Antisipasi naiknya harga minyak karena adanya krisis energi. Qtrly positif. Cashflow ud positif

=======================================================================

*** This is the opinion of the author, please consult your financial advisor and do your own test before investing. Pundireceh is not responsible for any obligations related to investment risk.

After fundamental analysis and technical analysis of price movements of Broadcom (NASDAQ:AVGO) and Doximity (NYSE:DOCS) over the last few months, we have decided to downgrade them to SELL and remove them from our portfolio. Meanwhile, for Kinder Morgan (NYSE:KMI) and Exxon Mobile Corp (NYSE:XOM) we raised their rating to BUY and added them to our portfolio.

Broadcom (NASDAQ:AVGO) downgrade to SELL

TA: Relatively sideways. Countdown target 462, daily, weekly 399
FA: Foundry overload and global logistics problems. Sell ​​for sector rotation

Doximity (NYSE:DOCS) downgraded to SELL

TA: Touch SMA50, but downtrend.
FA: No change on fundamental. To monitor earnings next Nov. Sell ​​for sector rotation

Kinder Morgan (NYSE:KMI) Upgrade to BUY

TA: Upward momentum, RSI,MACD up, Retrace at 17.3
FA: Qtrly positive. The cash flow is positive. China’s oil demand is high, the possibility of tension present in the South China Sea

Exxon Mobile (NYSE:XOM) Upgrade to BUY

TA: Bullish crossover. TP TA 65
FA: Sector rotation. Anticipate rising oil prices due to the energy crisis. Very positive. positive cash flow

Review stock analysis bulanan 31-September-2021

TickerPrice
today
USD
Days
in
portfolio
Profit /
Loss
Rating
NASDAQ:AVGO485.241043.0%BUY => SELL*
NASDAQ:INMD159.458365.9%BUY
NYSE:DOCS80.78367.1%BUY => SELL*
NASDAQ:XPEL75.8670-22.2%BUY
NYSE:YETI85.6964-10.8%BUY
NASDAQ:AMD102.9635.1%BUY
NASDAQ:TSLA775.486319.9%BUY
NASDAQ:NVDA207.0137-5.2%BUY
NYSE:SE318.7313-7.1%BUY
NASDAQ:KLAC334.516-9.2%BUY
NASDAQ:MSFT281.9228-6.6%BUY
NYSE:PG139.828-2.8%BUY
NASDAQ:CROX143.4813-10.9%BUY => SELL***
NASDAQ:BNTX272.9913-24.5%BUY
NYSE:BBWI63.036-6.5%BUY
Average
gain
2.3%
Bench
mark
S&P
500
-1.77%
* Downgrade to SELL on 1-Oct-21 ***Downgrade to SELL on 8-Oct-21

Pundi Receh ada di Tipranks.com untuk membandingkan diri kami dengan analis kelas dunia dan benchmark S&P500. Hasilnya Pundi Receh masih sejajar dengan Tipranks dan S&P500 untuk Bulan September. Silakan klik di bawah ini untuk lebih detail:

https://www.tipranks.com/investors/2153349/pundi-receh

=====================================================================

Pundi Receh is on Tipranks.com to compare ourselves to world class analysts and S&P500 benchmarks. The result is that Pundi Receh is still in comparable performance to Tipranks and S&P500 benchmark for the month of September. Please click below for more details:

https://www.tipranks.com/investors/2153349/pundi-receh

BIONTECH SE (NASDAQ:BNTX) Perusahaan biotechnology dalam penemuan obat (vaksin virus), immunoterapi dan cancer terapi untuk masa depan

by: Ivana

Latar Belakang

Nama : Biontech SE

Ticker : NASDAQ: BNTX

Harga: 277.44 $ (per 29 September 2021)

BioNTech SE, adalah sebuah perusahaan yang mengembangkan dan mengkomersialisasikan terapi dan penyembuhan untuk kanker dan penyakit menular lainnya. Sejak 2008 beberapa produk yang sedang dan telah dikembangkan adalah pengobatan kanker seperti kanker melanoma, prostat, payudara, untuk menyembuhkan HPV+ kanker kepala dan leher, ovarium dengan metode imunoterapi. Imunoterapi adalah salah satu cara untuk menyembuhkan kanker dengan menggunakan kekebalan tubuh kita sendiri. BioNtech sendiri telah mencapai pengujian tahap II dalam pengajuan metodenya tersebut. Saat ini, yang membuat Perusahaan ini dikenal, adalah karena telah berhasil mengembangkan vaksin COVID-19 yang telah di akui oleh FDA sejak 23 Aug 2021 dan telah disebarluaskan ke seluruh dunia dengan berkolaborasi dengan Pfizer Inc. Perusahaan-perusahaan lain yang telah berkolaborasi dengan BioNtech SE adalah Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; dan Regeneron Pharmaceuticals, Inc.

Tinjauan Industri

Sejak IPO 10 Sep 2019, dengan harga penawaran 15 $ – 16 $, saham BioNtech saat ini yang berada di harga 277.44 $ telah naik sebanyak 18.5 kali lipat.

Untuk masyarakat Amerika Serikat sendiri, mereka telah menerima vaksin Pfizer sebanyak hampir dua kali lipat dibanding pesaingnya Moderna, Inc. yang bisa dilihat dari grafik dibawah ini.

Ikhtisar Keuangan

Biontech telah melewati semua kriteria daftar checklist kami, kecuali Cash Flow Ratio dari net income. Hal ini dikarenakan peningkatan investasi perusahaan yang tinggi sebesar 480 persen selama satu tahun yang memperlihatkan kemungkinan adanya pertumbuhan investasi jangka panjang. Hal ini bisa terus dimonitor sehingga kita mengetahui apakah investasi jangka Panjang itu benar-benar berdampak terhadap hasil atau revenue yang diperoleh perusahaan.

Ringkasan Investasi

Teknologi Biontech saat ini masih digunakan oleh pasar dunia dikarenakan adanya vaksin covid 19 yang telah menjadi pandemic yang menyebar di seluruh dunia, dan 1-2 tahun kedepan akan adanya vaksin untuk anak2 dan booster untuk vaksin covid 19 yang telah mulai disebarkan di Amerika dimana Presiden Biden sendiri menggunakan vaksin ini.

Untuk jangka panjangnya, perusahaan Biontech terus melakukan penelitian dan pengembangan untuk vaksin flu, pneumonia, perawatan dan pengobatan penyakit kanker dan penyakit-penyakit lainnya.

Kompetisi Pasar

Di pasaran, Biontech bukan satu-satunya yang mengembangkan teknologi vaksin. Perusahaan seperti Moderna, Johnson and Johnson, dan perusahaan China seperti Sinovac dan Sinopharm juga membuat vaksin untuk covid 19 (hanya saja yang diakui oleh FDA saat ini baru Biontech) dimana yang lainnya adalah emergency approval.

Treatment NameCompanyFDA Approvaldata efficacy
Pfizer vaccine (Comirnaty)Biontech & Pfizer8/23/2021 Full approval95%
mRNA1273Moderna vaccineemergency authotization in US, EU and UK94.10%
NVX Cov2373Novavaxphase 390.40%
CoronaVacSinovacemergency use in China50.40%
SinopharmSinopharmaccepted in UAE and conditional approval in China86%
VaxzevriaAstraZenecaemergency authotization in UK, India and EU79%
JNJ78436735Johnson and Johnsonemergency authorization in US, EU and UK66%
Sumber: spglobal market intelligent website

Valuasi

MethodeTarget PricePotensi cuanPeriod
Discounted Cash FlowNANA1-3 years
Residual Earning39141%1-3 years
Technical AnalysisNANA3-6 months
Tipranks analyst average
(reference)
37336%NA
Artifical Intelligence
Kosho AI
(reference)
NA3.3%3 months

Sumber:

https://finance.yahoo.com/quote/BNTX/profile?p=BNTX
https://www.renaissancecapital.com/Profile/BNTX/BioNTech/IPO
https://www.usatoday.com/in-depth/graphics/2021/01/14/covid-vaccine-distribution-by-state-how-many-covid-vaccines-have-been-given-in-us-how-many-people/6599531002/

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

# BioNTech (NASDAQ:BNTX) sesuai dengan persyaratan syariah. Kondisi bisnis, produk, dan utangnya memenuhi kriteria Hukum Islam dan halal untuk diinvestasikan, berdasarkan analisis aplikasi Zoya (https://zoya.finance/).

===================================================================

by: Ivana

Background

Name : Biontech SE

Ticker : NASDAQ: BNTX

Price: 277.44 $ (as of September 29, 2021)

BioNTech SE, is a company that develops and commercializes therapies and cures for cancer and other infectious diseases. Since 2008 several products that are being and have been developed are cancer treatments such as melanoma, prostate, breast cancer, to cure HPV+ head and neck cancer, ovarian with immunotherapy methods. Immunotherapy is one way to cure cancer by using our own immunity. BioNtech itself has reached phase II testing in the submission of the method. Currently, what makes this Company known, is because it has successfully developed a COVID-19 vaccine that has been approved by the FDA since 23 Aug 2021 and has been distributed worldwide in collaboration with Pfizer Inc. Other companies that have collaborated with BioNtech SE are Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc.

Industry Overview

Since the IPO 10 Sep 2019, with an offering price of 15$ – 16$, BioNtech’s current stock at 277.44$ has gone up 18.5 times.

For the United States alone, they have received nearly twice as much Pfizer’s vaccine as its competitor Moderna, Inc. which can be seen from the graph below.

Financial Overview

Biontech has passed all of our checklist criteria, except Cash Flow Ratio from net income. This is due to the company’s high investment increase of 480 percent during one year which shows the possibility of long-term investment growth. This can be continuously monitored so that we know whether the long-term investment really has an impact on the results or revenue obtained by the company.

Investment Summary

Biontech technology is currently still used by the world market due to the covid 19 vaccine which has become a pandemic that has spread throughout the world, and in the next 1-2 years there will be a vaccine for children and a booster for the covid 19 vaccine which has begun to be spread in America where President Biden own use of this vaccine.

For the long term, the Biontech company continues to carry out research and development for flu vaccines, pneumonia, treatment and treatment of cancer and other diseases.

Market positioning

In the market, Biontech is not the only one developing vaccine technology. Companies such as Moderna, Johnson and Johnson, and Chinese companies such as Sinovac and Sinopharm are also making vaccines for COVID-19 (only Biontech is currently only recognized by the FDA).

Treatment NameCompanyFDA Approvaldata efficacy
Pfizer vaccine (Comirnaty)Biontech & Pfizer8/23/2021 Full approval95%
mRNA1273Moderna vaccineemergency authotization in US, EU and UK94.10%
NVX Cov2373Novavaxphase 390.40%
CoronaVacSinovacemergency use in China50.40%
SinopharmSinopharmaccepted in UAE and conditional approval in China86%
VaxzevriaAstraZenecaemergency authotization in UK, India and EU79%
JNJ78436735Johnson and Johnsonemergency authorization in US, EU and UK66%
Sumber: spglobal market intelligent website

Valuation

MethodeTarget PricePotensi cuanPeriod
Discounted Cash FlowNANA1-3 years
Residual Earning39141%1-3 years
Technical AnalysisNANA3-6 months
Tipranks analyst average
(reference)
37336%NA
Artifical Intelligence
Kosho AI
(reference)
NA3.3%3 months

Source

https://finance.yahoo.com/quote/BNTX/profile?p=BNTX
https://www.renaissancecapital.com/Profile/BNTX/BioNTech/IPO
https://www.usatoday.com/in-depth/graphics/2021/01/14/covid-vaccine-distribution-by-state-how-many-covid-vaccines-have-been-given-in-us-how-many-people/6599531002/

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

#BioNTech (NASDAQ:BNTX) complies with sharia requirements. The business conditions, products and debts meet the criteria of Islamic Law and are halal to invest in, based on the analysis of the Zoya application (https://zoya.finance/).

KLA Tencor (NASDAQ:KLAC), dan Bath and Body Works (NYSE:BBWI) upgrade rating ke BUY

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga KLA Tencor (NASDAQ:KLAC), dan Bath & Body Works (NYSE:BBWI) selama beberapa bulan terakhir, kami memutuskan untuk menaikkan rating mereka menjadi BUY dan memasukan ke dalam portfolio kami.

KLA Tencor (NASDAQ:KLAC)

Mendeteksi adanya pattern Elliot wave dengan ATH (All Time High)

Price: 369.8$ => Target Price: 483$

Bath & Body Works (NYSE:BBWI)

MACD menjadi hijau, dengan pattern Elliot wave

Price: 67.5$ => Target Price: 101$

Untuk analisa lengkapnya akan menyusul di postingan blog berikutnya, terima kasih.

=========================================================

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

After fundamental analysis and technical analysis (Technical Analysis) of the price movements of KLA Tencor (NASDAQ: KLAC), and Bath & Body Works (NYSE: BBWI) for the past few months, we have decided to raise their rating to BUY and add them in our portfolio.

KLA Tencor (NASDAQ:KLAC)

Detect Elliot wave pattern with ATH (All Time High)

Price: 369.8$ => Target Price: 483$

Bath & Body Works (NYSE:BBWI)

MACD turns green, with Elliot wave pattern

Price: 67.5$ => Target Price: 101$

For a complete analysis will be in the next blog post, thank you.

Sea Limited (NYSE:SE), Crocs Inc (NASDAQ:CROX) dan BioNTech (NASDAQ:BNTX) upgrade rating ke BUY

Setelah analisa fundamental dan analisa teknikal (Technical Analysis) pergerakan harga Sea Limited (NYSE:SE), Crocs Inc (NASDAQ:CROX) dan BioNTech (NASDAQ:BNTX) selama beberapa bulan terakhir, kami memutuskan untuk menaikkan rating mereka menjadi BUY dan memasukan ke dalam portfolio kami.

Sea Limited (NYSE:SE)

Mendeteksi adanya pattern falling wedge. Menuju ATH (All Time High)

Price: 339$ => Target Price: 386$

Crocs Inc (NASDAQ:CROX)

Mendeteksi pattern yang Bullish. Elliot Wave ke 5 menuju TP (Target Price)

Price: 155$ => Target Price: 174$

BioNTech (NASDAQ:BNTX)

Ada Elliot Wave pattern, dengan Elliot Wave ke-5 memiliki TP (Target Price) sangat tinggi

Price: 359$ => Target Price: 832$

Untuk analisa lengkapnya akan menyusul di postingan blog berikutnya, terima kasih.

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

=========================================================

After fundamental analysis and technical analysis of the price movements of Sea Limited (NYSE:SE), Crocs Inc (NASDAQ:CROX) and BioNTech (NASDAQ:BNTX) over the past few months, we have decided to raise their rating to BUY and add in our portfolio.

Sea Limited (NYSE:SE)

Detect a falling wedge pattern. Towards ATH (All-Time High)

Price: $339 => Target Price: $386

Crocs Inc (NASDAQ:CROX)

Detect a bullish pattern. 5th Elliot Wave towards TP (Target Price)

Price: $155 => Target Price: $174

BioNTech (NASDAQ:BNTX)

Detected Elliot Wave pattern. 5th Elliot Wave have high target price.

Price: $359 => Target Price: $832

The full analysis will be in the next blog post, thank you.

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

Shopify (NYSE:SHOP) downgrade rating ke SELL

Setelah analisa teknikal (Technical Analysis) pergerakan harga Shopify selama beberapa bulan terakhir, kami memutuskan untuk menurunkan rating Shopify menjadi SELL

Posting blog ada di sini NASDAQ:SHOP

Terima kasih

===================================================

After technical analysis on Shopify price movement for last few months, we decided to downgrade Shopify to SELL

Blog post is here NASDAQ:SHOP

Thank you

Procter and Gamble (NYSE:PG) produsen barang konsumen dengan pertumbuhan yang positif

Nama: P&G

Kode Ticker: NYSE:PG

Harga: 143.51 $ (per 8-Sep-2021)

Kategori: Large-Core

Sumber: yahoo finance

Sejak didirikan pada tahun 1837, Procter & Gamble telah menjadi salah satu produsen produk konsumen terbesar di dunia, menghasilkan lebih dari $75 miliar dalam penjualan tahunan. Perusahaan ini beroperasi dengan jajaran merek terkemuka, termasuk 21 merek yang masing-masing menghasilkan lebih dari $1 miliar dalam penjualan global tahunan, seperti deterjen cucian Tide, kertas toilet Charmin, sampo Pantene, dan popok Pampers. P&G tidak lagi memiliki merek makanan dengan melepasnya ke perusahaan lain dan yang terakhir, Pringles, ke Kellogg pada 2012. Penjualan di luar AS mewakili sekitar 55% dari total konsolidasi perusahaan, dengan sekitar sepertiga berasal dari pasar negara berkembang. P&G beroperasi dalam lima segmen: Kecantikan; Perawatan diri; Kesehatan; Kain & Perawatan Rumah; dan Perawatan Bayi, Wanita & Keluarga.

Tinjauan Industri

  1. Kecantikan (Beauty) : 19% dari penjualan bersih perusahaan dengan market share 15%. Avon (11%) adalah pesaing utama Procter & Gamble dan dikenal sebagai salah satu perusahaan kecantikan, rumah tangga, dan perawatan pribadi dengan penjualan langsung terbesar di dunia. Pesaing lainnya adalah Colgate-Palmolive, Estee Lauder, Revlon, and Unilever.
  2. Kain & Perawatan Rumah (Fabric & Home Care): Segmen bisnis terlaris perusahaan, mewakili 33% dari penjualan bersihnya dengan nama-nama seperti Tide, Bounce, Downy, dan Febreeze, dengan market share 10.7%. Pesaing utama Procter & Gamble di segmen ini termasuk nama merek seperti Palmolive, Ajax, dan Fleecy dari Colgate-Palmolive, Surf and Persil dari Unilever, dan lini produk Oxi Clean dan Arm & Hammer dari Church and Dwight Co.
  3. Perawatan Diri (Grooming): Gillette adalah pemain pasar yang dominan di segmen perawatan. Segmen ini menyumbang 9% dari penjualan bersih Procter & Gamble dengan market share 70%. Tetapi Bic adalah salah satu pesaing utamanya dengan kehadiran internasional yang besar. Segmen ini juga melihat peningkatan startup—terutama, di ruang cukur dengan nama seperti Dollar Shave Club (sekarang dimiliki oleh Unilever). P&G membeli perusahaan perawatan berbasis langganan Billie—salah satu yang pertama untuk wanita—pada Januari 2020 dengan jumlah yang tidak diungkapkan.
  4. Kesehatan (Healthcare): Segmen ini menyumbang 12% dari penjualan bersih dengan market share 4.8%.Anda mungkin akan mengenali nama-nama populer seperti Vicks, Pepto Bismol, dan Prilosec. Tetapi ada banyak perusahaan lain yang memberi P&G persaingan ketat. Pesaing utama seperti Colgate-Palmolive, Church and Dwight Co., Ecolab, Stepan Company, dan United-Guardian.
  5. Perawatan Bayi, Wanita & Keluarga (Baby, Feminine dan Family Care): P&G memiliki market share 35% di segmen perawatan bayi, wanita, dan keluarga. Pesaing utama termasuk Colgate-Palmolive—dengan nama merek seperti Tender Care—Zwitsal dari Unilever, dan Viviscal and Rephresh dari Church and Dwight Co. Segmen ini menyumbang 27% dari penjualan bersih Procter & Gamble dengan merek seperti Luvs, Bounty, dan Charmin.

Ringkasan Keuangan

Sumber: morningstar

P&G telah melewati semua kriteria daftar checklist kami, kecuali Current Ratio dan Quick Ratio. Hal ini karena P&G memiliki program kerjasama dengan supplier dan bank untuk perpanjangan jangka waktu pembayaran (extended payment terms) [1] Namun dengan interest coverage yang tinggi serta long term debt yang rendah, ini tidak menimbulkan kekhawatiran.

Ringkasan Investasi

Sebagai yang menjual barang-barang dasar kebutuhan sehari-hari, P&G bisa disebut sebagai defensive stock karena produknya selalu dibutuhkan. Meskipun ada beberapa pesaing namun dengan branding dan kualitas yang baik, P&G mampu mendapat profit margin yang cukup baik. PG tetap tangguh dalam lingkungan yang sulit, dengan fokusnya pada produktivitas dan penghematan biaya, yang telah meningkatkan keuntungan bagi marginnya. Penghematan biaya produksi didorong oleh program produktivitas lima tahun kedua (fiskal 2017-2021) yang mentargetkan penghematan $10 miliar.

Seluruh segmen usaha membukukan pertumbuhan penjualan organik, kecuali segmen Baby, Feminine dan Family Care. Penjualan organik masing-masing naik 6% di Beauty dan Grooming, 14% di Health Care, dan 2% di Fabric & Home Care. Namun, penjualan organik turun 1% di Baby, Feminine and Family Care.

Penilaian

MethodeTarget PricePotensi cuanPeriode
Discounted Cash Flow252.643%1-3 tahun
Residual Earning215.233%1-3 tahun
Technical Analysis152.05%3-6 bulan
Tipranks analyst average (reference)154.06%NA
Artifical Intelligence
Kosho AI (reference)
NA-1%3 bulan

[1] https://s1.q4cdn.com/695946674/files/doc_downloads/2021/08/PG_2021_Annual_Report.pdf

*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.

#P&G (NASDAQ: PG) sesuai dengan persyaratan syariah. Kondisi bisnis, produk, dan utangnya memenuhi kriteria Hukum Islam dan halal untuk diinvestasikan, berdasarkan analisis aplikasi Zoya (https://zoya.finance/).

==============================================

This image has an empty alt attribute; its file name is image-5.png

Name: P&G

Ticker Code: NYSE:PG

Price: 143.51$ (as of 8-Sep-2021)

Category: Large-Core

This image has an empty alt attribute; its file name is image-6.png
This image has an empty alt attribute; its file name is image-7-1024x490.png
Source: yahoo finance

Since its founding in 1837, Procter & Gamble has become one of the world’s largest manufacturers of consumer products, generating more than $75 billion in annual sales. The company operates under a range of leading brands, including 21 brands that each generate more than $1 billion in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo and Pampers diapers. P&G sold all food brands and most recently, Pringles, to Kellogg in 2012. Sales outside the US represent about 55% of the company’s consolidated total, with about a third coming from emerging markets. P&G operates in five segments: Beauty; Self care; Health; Fabrics & Home Care; and Baby, Women & Family Care.

Industry Overview

  1. Beauty : 19% of the company’s net sales with 15% market share. Avon (11%) is a major competitor to Procter & Gamble and is recognized as one of the largest direct selling beauty, home and personal care companies in the world. Other competitors are Colgate-Palmolive, Estee Lauder, Revlon, and Unilever.
  2. Fabrics & Home Care: The company’s best-selling business segment, representing 33% of its net sales with names such as Tide, Bounce, Downy and Febreeze, with a market share of 10.7%. Procter & Gamble’s main competitors in this segment include brands such as Palmolive, Ajax and Fleecy from Colgate-Palmolive, Surf and Persil from Unilever, and the Oxi Clean and Arm & Hammer product lines from Church and Dwight Co.
  3. Grooming: Gillette is a dominant market player in the grooming segment. This segment accounts for 9% of Procter & Gamble’s net sales with a market share of 70%. But Bic is one of its main competitors with a large international presence. This segment has also seen a rise in startups—notably, in barber shops with names like Dollar Shave Club (now owned by Unilever). P&G bought subscription-based care company Billie—one of its first for women—in January 2020 for an undisclosed amount.
  4. Health: This segment accounts for 12% of net sales with a market share of 4.8%. You may recognize popular names such as Vicks, Pepto Bismol, and Prilosec. But there are plenty of other companies that give P&G some tough competition. Major competitors include Colgate-Palmolive, Church and Dwight Co., Ecolab, Stepan Company, and United-Guardian.
  5. Baby, Feminine & Family Care: P&G has a 35% market share in the baby, women and family care segment. Key competitors include Colgate-Palmolive—with brand names such as Tender Care—Zwitsal from Unilever, and Viviscal and Rephresh from Church and Dwight Co. This segment accounts for 27% of Procter & Gamble’s net sales with brands such as Luvs, Bounty, and Charmin.

Financial Summary

This image has an empty alt attribute; its file name is image-8.png
Source: morningstar

P&G has passed all of our checklist criteria, except Current Ratio and Quick Ratio. This is because P&G has a cooperation program with suppliers and banks for extended payment terms [1] However, with high interest coverage and low long term debt, this is not a cause for concern.

Investment Summary

As a maker of basic daily necessities, P&G can be categorized as defensive stock because its products are always needed. Although there are several competitors, P&G has good branding and quality. P&G able to get a fairly good profit margin. PG has remained resilient in a difficult environment, with its focus on productivity and cost savings, which has increased its profit margins. Production cost savings were driven by the second five-year productivity program (fiscal 2017-2021) which targets $10 billion in savings.

All business segments recorded organic sales growth, except for the Baby, Feminine and Family Care segments. Organic sales increased by 6% in Beauty and Grooming, 14% in Health Care, and 2% in Fabric & Home Care, respectively. However, organic sales fell 1% at Baby, Feminine and Family Care.

Valuation

MethodeTarget PricePotensi cuanPeriod
Discounted Cash Flow252.643%1-3 years
Residual Earning215.233%1-3 years
Technical Analysis152.05%3-6 months
Tipranks analyst average
(reference)
154.06%NA
Artifical Intelligence
Kosho AI (reference)
NA-1%3 months
This image has an empty alt attribute; its file name is image-9-1024x520.png

[1] https://s1.q4cdn.com/695946674/files/doc_downloads/2021/08/PG_2021_Annual_Report.pdf

*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.

#P&G (NASDAQ:PG) complies with sharia requirements. The business conditions, products and debts meet the criteria of Islamic Law and are halal to invest in, based on the analysis of the Zoya application (https://zoya.finance/).